Metastasis

Gerstberger, Stefanie; Jiang, Qingwen; Ganesh, Karuna

doi:10.1016/j.cell.2023.03.003

Cited by 260 publications

(107 citation statements)

References 178 publications

Supporting

Mentioning

105

Contrasting

Unclassified

Order By: Relevance

“…[ 27 ] However, residual tumor cells or circulating tumor cells (CTCs) may cause lethal tumor recurrence and metastasis. [ 28 ] Activating tumor‐specific immune responses to prevent tumor relapse after surgery represents a promising strategy for cancer treatment. [ 29 ] To determine the anti‐recurrence effects of personalized tumor vaccines after surgical tumor resection, 90% of tumors were removed from orthotopic 4T1 tumor‐bearing mice, and the tumor cell membranes as the source of tumor antigens (Ag) which were collected from the resected 4T1 tumors were simply mixed with PEI@EcN and BG to fabricate the BG/Ag@EcN.…”

Section: Resultsmentioning

confidence: 99%

Engineered Probiotic‐Based Personalized Cancer Vaccine Potentiates Antitumor Immunity through Initiating Trained Immunity

Chen,

Yong,

Wei

et al. 2023

Advanced Science

View full text Add to dashboard Cite

Cancer vaccines hold great potential for clinical cancer treatment by eliciting T cell‐mediated immunity. However, the limited numbers of antigen‐presenting cells (APCs) at the injection sites, the insufficient tumor antigen phagocytosis by APCs, and the presence of a strong tumor immunosuppressive microenvironment severely compromise the efficacy of cancer vaccines. Trained innate immunity may promote tumor antigen‐specific adaptive immunity. Here, a personalized cancer vaccine is developed by engineering the inactivated probiotic Escherichia coli Nissle 1917 to load tumor antigens and β‐glucan, a trained immunity inducer. After subcutaneous injection, the cancer vaccine delivering model antigen OVA (BG/OVA@EcN) is highly accumulated and phagocytosed by macrophages at the injection sites to induce trained immunity. The trained macrophages may recruit dendritic cells (DCs) to facilitate BG/OVA@EcN phagocytosis and the subsequent DC maturation and T cell activation. In addition, BG/OVA@EcN remarkably enhances the circulating trained monocytes/macrophages, promoting differentiation into M1‐like macrophages in tumor tissues. BG/OVA@EcN generates strong prophylactic and therapeutic efficacy to inhibit tumor growth by inducing potent adaptive antitumor immunity and long‐term immune memory. Importantly, the cancer vaccine delivering autologous tumor antigens efficiently prevents postoperative tumor recurrence. This platform offers a facile translatable strategy to efficiently integrate trained immunity and adaptive immunity for personalized cancer immunotherapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Engineered Probiotic‐Based Personalized Cancer Vaccine Potentiates Antitumor Immunity through Initiating Trained Immunity

Chen,

Yong,

Wei

et al. 2023

Advanced Science

View full text Add to dashboard Cite

show abstract

“…In some harsh circumstances, the embryo will even stop developing until favorable conditions are restored 538,539 . Meanwhile, fetuses can regulate the immune microenvironment to evade attacks from the maternal immune system 540–544 …”

Section: Discussionmentioning

confidence: 99%

“…To date, researchers have made significant strides in understanding that cancer cells exhibit the remarkable capacity to mimic various specialized cell types. They can, for example, emulate neutrophils by entering the circulatory system and infiltrating different organs, engage in asymmetric differentiation akin to stem cells, and even establish communication with the nervous system 540–542 . For these reasons, many scientists now believe that the genesis of cancer cells is, in fact, a form of atavism 543 .…”

Section: Discussionmentioning

confidence: 99%

Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy

Cao,

Zhang,

Zhou

et al. 2023

MedComm

View full text Add to dashboard Cite

Emerging evidence indicates that cancer cells can mimic characteristics of embryonic development, promoting their development and progression. Cancer cells share features with embryonic development, characterized by robust proliferation and differentiation regulated by signaling pathways such as Wnt, Notch, hedgehog, and Hippo signaling. In certain phase, these cells also mimic embryonic diapause and fertilized egg implantation to evade treatments or immune elimination and promote metastasis. Additionally, the upregulation of ATP‐binding cassette (ABC) transporters, including multidrug resistance protein 1 (MDR1), multidrug resistance‐associated protein 1 (MRP1), and breast cancer‐resistant protein (BCRP), in drug‐resistant cancer cells, analogous to their role in placental development, may facilitate chemotherapy efflux, further resulting in treatment resistance. In this review, we concentrate on the underlying mechanisms that contribute to tumor development and progression from the perspective of embryonic development, encompassing the dysregulation of developmental signaling pathways, the emergence of dormant cancer cells, immune microenvironment remodeling, and the hyperactivation of ABC transporters. Furthermore, we synthesize and emphasize the connections between cancer hallmarks and embryonic development, offering novel insights for the development of innovative cancer treatment strategies.

show abstract

“…All compounds are >95% pure by HPLC analysis. Their structures were confirmed by 1 were evaluated by the MTT assay with platinum(II) drugs CDDP and OLP and platinum(IV) drug Satraplatin (JM216, STP) as reference drugs. Oxoplatin O1, DLT, and the DLT acid A3 were examined, and the mixture of CDDP with DLT (CDDP−DLT) was also tested to compare with the corresponding DLT platinum(IV) complexes.…”

Section: ■ Introductionmentioning

confidence: 99%

Series of Desloratadine Platinum(IV) Hybrids Displaying Potent Antimetastatic Competence by Inhibiting Epithelial–Mesenchymal Transition and Arousing Immune Response

Zhang,

Chen,

Liu

et al. 2024

J. Med. Chem.

View full text Add to dashboard Cite

Metastasis is the major obstacle to the survival of cancer patients. Herein, a series of new desloratadine platinum(IV) conjugates with promising antiproliferative and antimetastatic activities were developed and evaluated. The candidate complex caused significant DNA damage and stimulated mitochondrial apoptosis through the Bcl-2/Bax/caspase3 pathway. Then, it suppressed the epithelial–mesenchymal transition (EMT) process in tumors effectively through NMT-1/HPCAL1 and β-catenin signaling. Subsequently, the angiogenesis was inhibited with the downregulation of key proteins HIF-1α, VEGFA, MMP-9, and CD34. Moreover, the antitumor immunity was effectively aroused by the synergism of EMT reversion and decrease of the histamine level; then, the macrophage polarization from M2- to M1-type and the increase of CD4+ and CD8+ T cells were triggered simultaneously in tumors.

show abstract

Metastasis

Cited by 260 publications

References 178 publications

Engineered Probiotic‐Based Personalized Cancer Vaccine Potentiates Antitumor Immunity through Initiating Trained Immunity

Engineered Probiotic‐Based Personalized Cancer Vaccine Potentiates Antitumor Immunity through Initiating Trained Immunity

Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy

Series of Desloratadine Platinum(IV) Hybrids Displaying Potent Antimetastatic Competence by Inhibiting Epithelial–Mesenchymal Transition and Arousing Immune Response

Contact Info

Product

Resources

About